The latest news on cancer diagnostics, liquid biopsy, and cancer risk testing.
The tests will be developed to identify NSCLC patients with ALK fusions and EGFR Exon20 insertion mutations who respond to mobocertinib or brigatinib.
The company holds a leading position in reproductive testing and is expected to rapidly grow its oncology business to address a total market of $21 billion.
An expanded agreement grants Qiagen a non-exclusive development license to Bio-Techne's exosome technology for the development of companion diagnostic products.
Shares of Illumina fell in afternoon trading on the Nasdaq following a brief rise after the market open.
The companies will form a joint venture for Todos' cancer tests with Care GB owning 67 percent and Todos owning 33 percent of the new venture.
